The Advances in Gastrointestinal Cancer Resource Centre Introduction
The Advances in Gastrointestinal Cancer Resource Centre is dedicated to disseminating cutting edge data to practising healthcare professionals. Our aim is to provide clinically relevant information in order to enhance the caregivers' ability to provide optimal care for their gastrointestinal (GI) cancer patients. We will offer journal articles, patient case reports, interviews, and roundtable discussions with experts, with additional content aimed at expanding your expertise in the multidisciplinary field of GI cancer. This freely available resource, hosted by European Journal of Cancer and Clinical Colorectal Cancer, will function as a hub of information for healthcare professionals.
Our initial focus for Advances in Gastrointestinal Cancer will centre on gastric cancer, with future expansion to all GI malignancies. New content will be posted monthly, and the Editors encourage you to visit the site regularly to stay abreast of recent scientific developments in GI cancers. Please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.
Expert interviews from ESMO World Congress on Gastrointestinal Cancer
Article of the month
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction
Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, et al.
Ann Oncol 2016 Apr;27(4):660-7
Selected and commented by Prof. Florian Lordick:
In this randomized, controlled trial (referred to with the acronym NeoRes), which compared 3 cycles of cisplatin-5-fluorouracil neoadjuvant chemotherapy (nCT) with neoadjuvant chemoradiotherapy (nCRT) for oesophageal and gastro-esophageal junction carcinoma, the investigators have shown that nCRT significantly increases the proportion of complete histological response, increases the occurrence of ypN0 lymph-node status, and increases the R0 resection rate, but does so without a corresponding improvement in survival...
EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus
Birkman E-M, Ålgars A, Lintunen M, Ristamäki R, Sundström J, Carpén OBMC Cancer. 2016; 16: 406.
Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacopuzzi S, Aprile G, et al.Clin Cancer Res 2016 Jun 7 [Epub ahead of print]
Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review
Harada K, Baba Y, Shigaki H, Ishimoto T, Miyake K, Kosumi K, et al.BMC Cancer 2016 Jul 7;16:400.
A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)
Hideaki Bando, Toshihiko Doi, Kei Muro, Hirofumi Yasui, Tomohiro Nishina, Kensei Yamaguchi, Shunji Takahashi, Shogo Nomura, Hirofumi Kuno, Kohei Shitara, Akihiro Sato, Atsushi Ohtsu
European Journal of Cancer, July 2016, Pages 46 - 53
Low Preoperative Prognostic Nutritional Index Predicts Poor Survival Post-gastrectomy in Elderly Patients with Gastric Cancer
Sakurai K, Tamura T, Toyokawa T, Amano R, Kubo N, Tanaka H, et al.Ann Surg Oncol. 2016 May 20. [Epub ahead of print]